Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00462761 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT00462761 is a Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 76 participants.
The verdict
NCT00462761, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
Patients received oral AC220 daily for 14 days to study the side effects, tolerability and best dose for treating relapsed or refractory acute myeloid leukemia, regardless of FLT3 status.
Interventions
- DRUG AC220
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00462761
The ClinicalTrials.gov registry entry for NCT00462761 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AC220 is the first listed.
NCT00462761 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00462761 about?
NCT00462761 is a clinical study titled "A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status". Patients received oral AC220 daily for 14 days to study the side effects, tolerability and best dose for treating relapsed or refractory acute myeloid leukemia, regardless of FLT3 status.
What is the current status of trial NCT00462761?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2007-01. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00462761?
The interventions under investigation include: AC220 (DRUG).
Who is sponsoring clinical trial NCT00462761?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.